AI Generated Image
GLP-1 weight loss pills may be bad thing for job insurance coverage
CNBC • • business
Key Points:
- Novo Nordisk and Eli Lilly have introduced oral GLP-1 weight-loss pills priced similarly to injectables, increasing consumer demand but raising concerns among employers about rising insurance costs.
- Nearly half of large employers covered GLP-1 drugs in 2025, but over half cite these medications as a leading factor in rising prescription costs, making coverage financially unsustainable for many.
- Employers worry about high upfront costs and uncertain long-term benefits, especially as some patients discontinue use and regain weight, leading to potential cuts or stricter coverage criteria in 2026 and 2027.
- Some companies may exclude oral GLP-1 pills from coverage or offer alternative programs like health reimbursement arrangements or third-party weight management services to control expenses.
- While federal initiatives and increased market competition may lower GLP-1 prices in the future, high costs persist currently, causing employers to remain cautious about expanding or maintaining coverage.
